115 non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy imaged with FDG PET/CT at baseline and post-treatment
Each lesion was quantified and matched between timepoints using TRAQinform IQ™ technology. Heterogeneity of response among individual lesions correlates to overall clinical outcome.
Figure: Each bar on chart represents an individual patient showing how each of their lesions are responding to treatment. Each lesion is detected, quantified and categorized as new, progressing, stable, partially responding or completely responding.
AIQ Score is an all-inclusive patient lesion analytics metric. It is calculated by using a proprietary AI algorithm that produces a single numeric value which predicts treatment response at the patient level. This multi-faceted metric has been validated across multiple large data sets.
The chart above indicates a prediction of a individual patient's clinical outcome compared to a population.
Retrospective 57 patient Phase I/II study comparing AIQ technology to experienced reader for evaluating heterogeneous system amyloid build up in multiple organs.
“This approach will significantly impact the ease of use and improve accuracy of image interpretation that will ultimately benefit clinical management of patients with amyloidosis.”
Study of 35 melanoma patients in ICI therapy. All patients received 3 FDG PET/CT scans. Changes in SUV uptake were compared between healthy patients and those who developed colitis.
AIQ predicted which patients would develop colitis 50 days prior to actual diagnosis.
Study of 35 patients with metastatic GEP-NETs treated with Lutathera receiving GA-DOTATATE PET/CT
Early decrease in bone marrow SUV correlates to decrease in platelet count. Baseline SUV identified patients with increase in creatinine levels.
AIQ's software has been cleared for clinical use under 510(k) K173444. For details, including the applicable Indications for Use, see: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K173444
